News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Jeffrey S. Williams Joins Alexza Molecular Delivery Corporation (MDC) As Senior Vice President



10/19/2005 5:10:38 PM

PALO ALTO, Calif., March 30 /PRNewswire/ -- Alexza Molecular Delivery Corporation ("Alexza") announced today that Jeffrey S. Williams has joined the company as Senior Vice President, Corporate and Business Development. Mr. Williams, a 15-year industry veteran, will have primary responsibility for corporate and business development, facility operations and information technology. From 2001 to 2004, Mr. Williams was Vice President, Corporate Development and a member of the founding management team at Scion Pharmaceuticals, Inc. He was Vice President, Office of Development at Anesta Corp. until 2001, when Anesta was acquired by Cephalon, Inc. He started his career with positions at Phase V Technologies, Inc. and Vertex Pharmaceuticals, Inc.

"I am very pleased to welcome Jeff to our Alexza management team," said Thomas B. King, President and CEO. "The combination of Jeff's passion for success and his leadership expertise represents an ideal phenotype to lead our business and corporate development efforts."

"I am thrilled to be joining Alexza, with its creative and committed team of scientists, engineers and staff," said Williams. "Alexza's novel technologies will provide substantial business and corporate development opportunities."

Dr. Alejandro Zaffaroni, renowned biotechnology pioneer and investor, founded Alexza. Alexza is a specialty pharmaceutical company developing products using the company's core platform, Staccato(TM) technology. The Staccato(TM) technology enables the rapid onset of therapeutic effect of many small molecule drugs as well as patient titration to the lowest effective dose to better treat acute and intermittent conditions. In addition to developing its own pipeline, focusing initially on central nervous system indications representing more than $15 billion in annual US sales, the company plans to also strategically partner its technology with pharmaceutical companies.

Alexza Molecular Delivery Corporation

CONTACT: Thomas B. King, President & CEO of Alexza Molecular DeliveryCorporation, +1-650-687-3902


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES